^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RG6286
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
CD3 agonist, LY6G6D inhibitor
Related drugs:
Phase 1
Genentech, Inc.
Completed
Last update posted :
02/10/2025
Initiation :
08/31/2020
Primary completion :
10/16/2024
Completion :
10/16/2024
MSI
|
RG6286
Share
